Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s valuation beyond $500bn.
诺和诺德(Novo Nordisk)已同意以110亿美元的价格收购三个生产基地，这家丹麦制药商正在努力扩大减肥药的生产，减肥药的大获成功使该公司的估值超过了5000亿美元。
您已阅读6%（303字），剩余94%（4418字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。